Gandi Capsule Improved Podocyte Lipid Metabolism of Diabetic Nephropathy Mice through SIRT1/AMPK/HNF4A Pathway

Figure 6

The expressions of podocin, SIRT1, p-AMPKα, total AMPKα, and HNF4A in MPC-5 after treatment with different concentration of GDC (5, 25, and 125 μg/mL) and baicalin (3, 6, and 12 μmol/L) for 24 hours. (a–f) The protein levels of podocin, SIRT1, p-AMPKα, total AMPKα, and HNF4A were analyzed in MPC-5 treated with (a, c, and e) GDC or (b, d, and f) baicalin by western blot. (g–j) Quantitative analyses of the GDC results from the blot were shown: (g) podocin/β-actin; (h) SIRT1/β-actin; (i) p-AMPKα/total AMPKα; and (j) HNF4A/β-actin. (k–n) Quantitative analyses of the baicalin results from the blot were shown: (k) podocin/β-actin; (l) SIRT1/β-actin; (m) p-AMPKα/total AMPKα; and (n) HNF4A/β-actin. , , and .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)